๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Leukemia, Myeloid, Acute
Clinical trial register · China

Leukemia, Myeloid, Acute Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 4 Beijing 4 Hangzhou 3 Chengdu 3 Hefei 3
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou4 Beijing4 Hangzhou3 Chengdu3 Hefei3
All 18 locations
Target enrolment
to

Leukemia, Myeloid, Acute trials in China

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT06852222Leukemia, Myeloid, Acute
Janssen Research & Development, LLC
Phase 3
600
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan
2025-06-04
By invitation
Daunorubicin + Cytarabine + Venetoclax in de Novo AML
NCT06697327Leukemia, Myeloid, Acute, Acute Myeloid Leukemia
Anhui Medical University
Not applicable
94
Hefei
2025-02-01
By invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
Janssen Research & Development, LLC
Phase 1
120
2024-12-30
Recruiting
Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy
NCT06643962Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute
Affiliated Hospital of Nantong University
Not applicable
83
Nantong
2024-10-31
Not yet open
Hema-NeoTIL01 Cell Infusion Therapy in Relapsed/Refractory Acute Leukemia
NCT06559644Leukemia, Myeloid, Acute, B-cell Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Soochow University
Phase EARLY_PHASE1
20
Suzhou
2024-09-01
Recruiting
Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
NCT06118788Leukemia, Myeloid, Acute
Guangzhou Bio-gene Technology Co., Ltd
Phase 1/2
24
Guangzhou, Hangzhou
2024-03-07
Recruiting
Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT
NCT05682755Leukemia, Myeloid, Acute
Sichuan University
Phase 1/2
77
Chengdu
2022-12-22
Recruiting
VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT05603884Leukemia, Myeloid, Acute, AML Stage, Adult
The First Affiliated Hospital of Xiamen University
Phase 2
66
Xiamen
2022-12-01
Active, closed
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
NCT05413018Leukemia, Myeloid, Acute
Bristol-Myers Squibb
Phase 2
34
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Shijiazhuang, Xuzhou, Shenyang
2022-08-19
Recruiting
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
NCT05270200Leukemia, Myeloid, Acute
Zhujiang Hospital
Phase 1/2
40
Guanzhou
2022-02-01
Recruiting
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
NCT05305859Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2022-01-12
Recruiting
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT
NCT03793517Stem Cell Transplant Complications, Leukemia, Myeloid, Acute, Leukemia Relapse
Peking University People's Hospital
Phase 2/3
55
Beijing
2018-09-01
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
Institut de Recherches Internationales Servier
Phase 3
146
Zhengzhou, Chengdu, Beijing, Guangzhou, Hangzhou, Tianjin
2017-06-26
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/leukemia-myeloid-acute

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies listing the condition Leukemia, Myeloid, Acute.

How many Leukemia, Myeloid, Acute trials are recruiting in China?

8 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 2 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Leukemia, Myeloid, Acute), 13 studies
PhaseStudiesRecruitingShare
Phase 1/23323.1%
Phase 23223.1%
Not applicable2115.4%
Phase 32115.4%
Phase 1107.7%
Phase 2/3117.7%
Phase EARLY_PHASE1107.7%

Most active sponsors

Lead sponsors with the most studies (Leukemia, Myeloid, Acute)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC21
The First Affiliated Hospital of Xiamen University22
Affiliated Hospital of Nantong University11
Anhui Medical University10
Bristol-Myers Squibb10
Guangzhou Bio-gene Technology Co., Ltd11
Institut de Recherches Internationales Servier10
Peking University People's Hospital11
Sichuan University11
The First Affiliated Hospital of Soochow University10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.